Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Posted by Stanley Muller on Aug 19th, 2026

Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 47,941 shares, a decline of 45.6% from the July 15th total of 88,087 shares. Based on an average trading volume of 242,713 shares, the days-to-cover ratio is presently 0.2 days. Currently, 4.7% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th.

View Our Latest Analysis on Clearmind Medicine

Clearmind Medicine Price Performance

Shares of NASDAQ CMND opened at $1.96 on Wednesday. Clearmind Medicine has a 1-year low of $1.43 and a 1-year high of $524.00. The business’s 50 day moving average is $2.16 and its two-hundred day moving average is $6.50. The stock has a market capitalization of $2.00 million, a P/E ratio of -0.01 and a beta of 0.75.

Clearmind Medicine (NASDAQ:CMND – Get Free Report) last posted its quarterly earnings data on Monday, June 15th. The company reported ($6.78) earnings per share (EPS) for the quarter.

Insider Transactions at Clearmind Medicine

In other news, major shareholder Financial Lp Hrt sold 22,139 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total transaction of $73,280.09. Following the sale, the insider directly owned 81,353 shares of the company’s stock, valued at $269,278.43. This represents a 21.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 252,615 shares of company stock valued at $117,933.

About Clearmind Medicine

(Get Free Report)

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.